Iodine-131 tositumomab [Bexxar] is effective in B-cell lymphoma that has progressed after rituximab therapy

Author：  

Publisher： Adis International

ISSN： 1173-8324

Source： Inpharma, Vol.1, Iss.1482, 2005-01, pp. : 15-15

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Rituximab + CHOP: first-line therapy in B-cell lymphoma

By  

Inpharma, Vol. 1, Iss. 1323, 2002-01 ,pp. : 14-14

Adis International

Access to resources Recommend Favorite

Iodine-131 tositumomab after CHOP promising for follicular NHL

By  

Inpharma, Vol. 1, Iss. 1551, 2006-01 ,pp. : 10-10

Adis International

Access to resources Recommend Favorite

A CHOP regimen is effective for post-transplant lymphoproliferative disorders (PTLD) that have progressed after first-line therapy with rituximab

By  

Inpharma, Vol. 1, Iss. 1588, 2007-01 ,pp. : 18-18

Adis International

Access to resources Recommend Favorite

Risk factors for developing infusion reaction after rituximab administration in patients with B-cell non-Hodgkin's lymphoma

By Tachi T.   Yasuda M.   Usui K.   Umeda M.   Nagaya K.   Osawa T.   Ichihashi A.   Noguchi Y.   Goto H.   Kasahara S.   Takahashi T.   Goto C.   Teramachi H.  

Die Pharmazie - An International Journal of Pharmaceutical Sciences, Vol. 70, Iss. 10, 2015-10 ,pp. : 674-677

Govi-Verlag

Access to resources Recommend Favorite

Iodine-131 tositumomab promising in refractory NHL

By  

Inpharma, Vol. 1, Iss. 1312, 2001-01 ,pp. : 12-12

Adis International

Access to resources Recommend Favorite